Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.
Animals
Carbon Tetrachloride
/ administration & dosage
Collagen
/ analysis
Disease Models, Animal
Disease Progression
Elasticity Imaging Techniques
/ methods
Ethanol
/ administration & dosage
Fatty Liver, Alcoholic
/ diagnostic imaging
Female
Hepatitis, Alcoholic
/ diagnostic imaging
Interleukins
/ administration & dosage
Liver
/ chemistry
Liver Cirrhosis
/ diagnostic imaging
Liver Diseases, Alcoholic
/ diagnostic imaging
Male
Mice
Mice, Inbred C57BL
Multiparametric Magnetic Resonance Imaging
/ methods
Non-alcoholic Fatty Liver Disease
/ diagnostic imaging
Sensitivity and Specificity
Interleukin-22
damping ratio
liver stiffness
magnetic resonance elastography
magnetic resonance imaging
proton density fat fraction
Journal
Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
25
07
2021
received:
07
04
2021
accepted:
13
08
2021
pubmed:
7
9
2021
medline:
5
3
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Magnetic resonance imaging (MRI) and MRI-based elastography (MRE) are the most promising noninvasive techniques in assessing liver diseases. The purpose of this study was to evaluate an advanced multiparametric imaging method for staging disease and assessing treatment response in realistic preclinical alcohol-associated liver disease (ALD). We utilized four different preclinical mouse models in our study: Model 1-mice were fed a fast-food diet and fructose water for 48 weeks to induce nonalcoholic fatty liver disease; Model 2-mice were fed chronic-binge ethanol (EtOH) for 10 days or 8 weeks to induce liver steatosis/inflammation. Two groups of mice were treated with interleukin-22 at different time points to induce disease regression; Model 3-mice were administered CCl Multiparametric models with combinations of biomarkers (LS, LM, DR, and PDFF) used noninvasively to predict the histologic severity and regression of steatosis, inflammation, and fibrosis were highly accurate (area under the curve > 0.84 for all). A three-parameter model that incorporates LS, DR, and ALT predicted histologic fibrosis progression (r = 0.84, p < 0.0001) and regression (r = 0.79, p < 0.0001) as measured by collagen content in livers. This preclinical study provides evidence that multiparametric MRI/MRE can be used noninvasively to assess disease severity and monitor treatment response in ALD.
Sections du résumé
BACKGROUND
Magnetic resonance imaging (MRI) and MRI-based elastography (MRE) are the most promising noninvasive techniques in assessing liver diseases. The purpose of this study was to evaluate an advanced multiparametric imaging method for staging disease and assessing treatment response in realistic preclinical alcohol-associated liver disease (ALD).
METHODS
We utilized four different preclinical mouse models in our study: Model 1-mice were fed a fast-food diet and fructose water for 48 weeks to induce nonalcoholic fatty liver disease; Model 2-mice were fed chronic-binge ethanol (EtOH) for 10 days or 8 weeks to induce liver steatosis/inflammation. Two groups of mice were treated with interleukin-22 at different time points to induce disease regression; Model 3-mice were administered CCl
RESULTS
Multiparametric models with combinations of biomarkers (LS, LM, DR, and PDFF) used noninvasively to predict the histologic severity and regression of steatosis, inflammation, and fibrosis were highly accurate (area under the curve > 0.84 for all). A three-parameter model that incorporates LS, DR, and ALT predicted histologic fibrosis progression (r = 0.84, p < 0.0001) and regression (r = 0.79, p < 0.0001) as measured by collagen content in livers.
CONCLUSION
This preclinical study provides evidence that multiparametric MRI/MRE can be used noninvasively to assess disease severity and monitor treatment response in ALD.
Identifiants
pubmed: 34486129
doi: 10.1111/acer.14699
pmc: PMC8602761
mid: NIHMS1735176
doi:
Substances chimiques
Interleukins
0
Ethanol
3K9958V90M
Collagen
9007-34-5
Carbon Tetrachloride
CL2T97X0V0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2103-2117Subventions
Organisme : NIAAA NIH HHS
ID : UH3 AA026887
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA021171
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB017197
Pays : United States
Organisme : NIAAA NIH HHS
ID : UH2 AA026887
Pays : United States
Organisme : NIBIB NIH HHS
ID : R37 EB001981
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB001981
Pays : United States
Organisme : NIAAA NIH HHS
ID : R37 AA021171
Pays : United States
Informations de copyright
© 2021 by the Research Society on Alcoholism.
Références
J Lipid Res. 2004 Aug;45(8):1410-7
pubmed: 15145986
Eur Radiol. 2021 Dec;31(12):9468-9478
pubmed: 34023968
Top Magn Reson Imaging. 2018 Oct;27(5):319-333
pubmed: 30289828
Abdom Imaging. 2015 Apr;40(4):818-34
pubmed: 24711064
J Magn Reson Imaging. 2015 May;41(5):1203-8
pubmed: 24889753
Eur Radiol. 2019 Nov;29(11):5823-5831
pubmed: 30887196
Gut Liver. 2016 Sep 15;10(5):672-86
pubmed: 27563019
J Hepatol. 2020 Dec;73(6):1322-1332
pubmed: 32610115
Hepatology. 2019 Oct;70(4):1377-1391
pubmed: 30963615
Gastroenterology. 2017 Sep;153(3):753-761
pubmed: 28624576
J Liver. 2019;8(1):
pubmed: 31341723
Gastroenterology. 2016 Mar;150(3):626-637.e7
pubmed: 26677985
Radiology. 2017 Sep;284(3):694-705
pubmed: 28128707
Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2
pubmed: 17916548
Radiology. 2016 Jan;278(1):114-24
pubmed: 26162026
Gut. 2020 Apr;69(4):764-780
pubmed: 31879281
Hepatology. 2010 Oct;52(4):1291-300
pubmed: 20842630
Clin Gastroenterol Hepatol. 2015 Mar;13(3):440-451.e6
pubmed: 25305349
Hepatology. 2017 Nov;66(5):1486-1501
pubmed: 28586172
Gastroenterology. 2017 Jul;153(1):233-248.e16
pubmed: 28363640
Radiology. 2018 Jun;287(3):824-832
pubmed: 29470938
J Hepatol. 2019 Sep;71(3):586-593
pubmed: 31173814
Gut. 2020 Sep;69(9):1677-1690
pubmed: 31992593
Hepatol Int. 2014 Sep;8 Suppl 2:475-80
pubmed: 26201327
Biomedicines. 2019 Sep 05;7(3):
pubmed: 31491888
J Magn Reson Imaging. 2012 Nov;36(5):1011-4
pubmed: 22777847
Hepatology. 2012 Sep;56(3):1150-9
pubmed: 22473749
Gut. 2006 Apr;55(4):569-78
pubmed: 16531536
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Clin Biochem. 1996 Jun;29(3):225-9
pubmed: 8740508
Hepatol Res. 2017 Apr;47(5):455-464
pubmed: 27351583
J Hepatol. 2013 Nov;59(5):992-8
pubmed: 23838178
Hepatology. 2020 Feb;71(2):510-521
pubmed: 30582669
Congenit Heart Dis. 2014 Jan-Feb;9(1):7-14
pubmed: 24134059
Nat Rev Dis Primers. 2018 Aug 16;4(1):16
pubmed: 30115921
Clin Liver Dis. 2016 Aug;20(3):473-89
pubmed: 27373610
J Hepatol. 2016 Nov;65(5):1006-1016
pubmed: 27312947
J Clin Invest. 2007 Mar;117(3):539-48
pubmed: 17332881